Abstract: Protein constructs comprising a BTNL3/8 targeting moiety, a payload and an optional linker are described herein. Pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Abstract: The invention relates to methods for expanding ?? T cells comprising preparing a composition enriched for ?? T cells and culturing the composition in the presence of feeder cells. Also provided is a method for engineering ?? T cells comprising preparing a composition enriched for ?? T cells, transducing the composition to express a chimeric antigen receptor (CAR) specific for a tumour associated antigen and culturing the transduced composition to expand the engineered ?? T cells. Also provided are expanded and engineered ?? T cells produced according to the described methods, which find utility in adoptive T cell therapies, chimeric receptor therapies and the like.

Abstract: The invention relates to compositions comprising NaturalKiller (NK) cells and ?? T cells, particularly for use in adoptive immunotherapy. The invention also provides method for preparing such compositions which comprises contacting a sample with an anti-TCR delta variable 1 (anti-V?1) antibody.

Abstract: The invention relates to methods for the isolation of non-haematopoietic tissue-resident lymphocytes, particularly ?? T cells. Such ?? T cells include non-V?2 cells, e.g. V?1, V?3 and V?5 cells and such non-haematopoietic tissues include skin and gut. It will be appreciated that such isolated non-haematopoietic tissue-resident lymphocytes find great utility in adoptive T cell therapies, chimeric receptor therapies and the like. Also provided are methods for expanding isolated tissue-resident lymphocytes, particularly methods for isolating and expanding ?? T cells. The present invention also relates to both individual cells and populations of cells produced by the methods described herein.

Abstract: The invention relates to ex vivo methods of modulating gamma variable 4 (V?4) T cells using antibodies or fragments thereof, which specifically bind to a V?4 chain of a ?? T cell receptor (TCR) and not to a gamma variable 2 (V?2) chain of a ?? TCR. Methods of treatment and other uses of expanded populations of V?4 T cells produced by said methods are also provided.

Abstract: The invention relates to compositions comprising V?1+ T cells, for use in treating myeloid malignancies. The present invention also relates to methods of treatment using said compositions.

Abstract: An isolated antibody or fragment thereof, which specifically binds to a gamma variable 4 (V?4) chain of a ?? T cell receptor (TCR) and not to a gamma variable 2 (V?2) chain of a ?? TCR is provided herein. Methods of treatment and other uses of said antibodies are also provided along with methods of producing said antibodies.

Abstract: The present invention provides methods of expanding ?? T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded ?? T cells and methods of using the expanded ?? T cells (e.g., apart of an adoptive T cell therapy).